title: Medical abortion options may advance in 1998.
mesh_terms: D000028:Abortion, Induced; D000569:Americas; D001695:Biology; D002986:Clinical Trials as Topic; D003132:Commerce; D019049:Developed Countries; D004467:Economics; D004703:Endocrine System; D005193:Family Planning Services; D006077:Government Agencies; D006727:Hormone Antagonists; D006728:Hormones; D007603:Jurisprudence; D015735:Mifepristone; D016595:Misoprostol; D009656:North America; D009934:Organization and Administration; D009938:Organizations; D010827:Physiology; D017149:Private Sector; D016730:Program Development; D011453:Prostaglandins; D011465:Prostaglandins, Synthetic; D012106:Research; D014481:United States; D014486:United States Food and Drug Administration; D014492:United States Public Health Service
chemical_list: D006727:Hormone Antagonists; D006728:Hormones; D011453:Prostaglandins; D011465:Prostaglandins, Synthetic; D016595:Misoprostol; D015735:Mifepristone
keywords: Abortion, Drug Induced; Abortion, Induced; Americas; Biology; Clinical Research; Clinical Trials; Commerce; Commercial Sector; Developed Countries; Economic Factors; Endocrine System; Family Planning; Fertility Control, Postconception; Government Agencies; Hormone Antagonists; Hormones; Litigation; Macroeconomic Factors; Misoprostol; North America; Northern America; Obstacles; Organization And Administration; Organizations; Physiology; Private Sector; Progress Report; Prostaglandins; Prostaglandins, Synthetic; Research Methodology; Ru-486; United States; Usfda; Usphs